৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Quantity:
Products
Payment
Delivery
Indications
Vortiox is indicated for the treatment of major depressive disorder (MDD) in adults.
Pharmacology
The mechanism of the antidepressant effect of Vortioxetine is not fully understood, but it is thought to be related to its enhancement of serotonergic activity in the central nervous system through
inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
Dosage & Administration
Recommended dose: The recommended starting dose is 10 mg administered orally once daily without regard to meals. The dosage should then be increased to 20 mg/day, as tolerated. The efficacy and
safety of doses above 20 mg/day have not been evaluated in controlled clinical trials. A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses. The lowest
effective dose of 5 mg/day should always be used as the starting dose for elderly patients (>65 years of age).
Maintenance dose: For MDD, Vortioxetine can be administered for several months or longer. For a long period use patients should be re-evaluated to assess the usefulness of the drugs for individual
patients.
Discontinuation treatment: Although Vortioxetine can be abruptly discontinued, in placebo-controlled trials patients experienced transient adverse reactions such as headache and muscle tension
following abrupt discontinuation of Vortioxetine 15 mg/day or 20 mg/day. To avoid these adverse reactions, it is recommended that the dose should be decreased to 10 mg/day for one week before full
discontinuation of Vortioxetine 15 mg/day or 20 mg/day.
Switching a patient to or from a Monoamine Oxidase Inhibitor (MAOI) intended to treat Psychiatric Disorders: At least 14 days must elapse between discontinuation of an MAOI intended to treat
psychiatric disorders and initiation of therapy with Vortioxetine to avoid the risk of Serotonin Syndrome. Conversely, at least 21 days must elapse after stopping Vortioxetine before starting an MAOI
intended to treat psychiatric disorders.
Interaction
Monoamine Oxidase Inhibitors: Adverse reactions, some of which are serious or fatal, can develop in patients who use MAOls or who have recently been discontinued from an MAOI and started on a
serotonergic antidepressant(s) or who have recently had SSRI or SNRI therapy discontinued prior to initiation of an MAOI.
Serotonergic drugs: Co-administration of Vortiox with other drugs that may affect the serotonergic neurotransmitter systems (e.g. SSRIs, SNRIs, Triptans, Buspirone, Tramadol, and Tryptophan
products etc.) may potentially increase serotonin toxicity or serotonin syndrome. Closely monitor symptoms of serotonin syndrome if Vortiox is co-administered with other serotonergic drugs.
Treatment with Vortiox and any concomitant serotonergic agents should be discontinued immediately if serotonin syndrome occurs.
Other CNS active agents: No clinically relevant effect was observed on steady-state Lithium exposure following co-administration with multiple daily doses of Vortiox.
Potential for other drugs to affect Vortiox: Reduce Vortiox dose by half when a strong CYP2D6 inhibitor (e.g. Bupropion, Fuoxetine, Paroxetine, Quinidine) is co-administered. Consider increasing the
Vortiox dose when a strong CYP inducer (e.g. Rifampin, Carbamazepine, Phenytoin) is co-administered.
Contraindications
Vortioxetine Hydrobromide is contraindicated in Patients with known hypersensitivity to Vortioxetine or any of the excipients of the drug product & concomitant use of Monoamine Oxidase Inhibitors
(MAOIs).
Side Effects
Patients taking Vortiox may experience some adverse events such as Hypersensitivity, Clinical worsening and suicide risk, Serotonin syndrome, Abnormal bleeding, activation of Mania/Hypomania,
Angle closure Glaucoma, Hyponatremia.
Pregnancy & Lactation
The safety of Vortioxetine in human pregnancy has not been established. Therefore, Vortioxetine should not be used during pregnancy or in women intending to become pregnant, unless the benefits
outweigh the possible risks to the fetus. Available data in animals have shown the excretion of Vortioxetine metabolites in milk. It is expected that Vortioxetine will be excreted into human milk. Because





Vortioxetine Hydrobromide is a prescription antidepressant used to treat major depressive disorder (MDD). It works by modulating serotonin activity in the brain—blocking and stimulating different serotonin receptors while also inhibiting serotonin reuptake.
Vortioxetine is used for depression, low mood, lack of interest, anxiety symptoms associated with depression, and cognitive symptoms like poor concentration. It may improve mood, energy, and mental clarity.



